ReviewFrontiers in cardiovascular medicine2025
To clip or not to clip? A review of precise risk assessment in the contemporary era of transcatheter edge-to-edge mitral and tricuspid valve repair.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter edge-to-edge mitral and tricuspid valve repair (M-TEER, T-TEER) have emerged as meaningful treatment modalities among patients at high surgical risk suffering from valvular heart disease. While previous research has shown that optimal patient selection is crucial for treatment outcomes, recent studies have identified a multitude of factors that independently influence mortality. Although these findings can significantly support clinical decision-making, the large number of available studies renders an overview of this topic challenging. In this review, we provide a comprehensive overview of the currently identified factors associated with increased mortality after TEER. We also summarize the current evidence on published risk scores that stratify mortality risk after M-TEER and T-TEER. We aimed to provide clinical decision-making support for optimal patient selection and referral to TEER and to identify remaining gaps in evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.